{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:50:37Z","timestamp":1791474637798,"version":"4.3.4"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Basic Research Program of China","award":["2015CB931800"],"award-info":[{"award-number":["2015CB931800"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773620"],"award-info":[{"award-number":["81773620"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573332"],"award-info":[{"award-number":["81573332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31872746"],"award-info":[{"award-number":["31872746"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Funds","award":["18431902800"],"award-info":[{"award-number":["18431902800"]}]},{"name":"Scientific Research Projects of Shanghai Municipal Commission of Health and Family Planning","award":["201740140"],"award-info":[{"award-number":["201740140"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0812-9","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T15:04:53Z","timestamp":1576076693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer"],"prefix":"10.1136","volume":"7","author":[{"given":"Xuyao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-9622","authenticated-orcid":false,"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"key":"812_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"812_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"key":"812_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579\u201391.","journal-title":"Nat Rev Cancer"},{"key":"812_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388:518\u201329.","journal-title":"Lancet"},{"key":"812_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3322\/caac.21411","volume":"67","author":"PC Barata","year":"2017","unstructured":"Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67:507\u201324.","journal-title":"CA Cancer J Clin"},{"key":"812_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322.","journal-title":"Cancer Cell"},{"key":"812_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471\u201394.","journal-title":"Angiogenesis."},{"key":"812_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592\u2013603.","journal-title":"Nat Rev Cancer"},{"issue":"385","key":"812_CR9","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"Elizabeth Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.aak9679\n\n.","journal-title":"Science Translational Medicine"},{"key":"812_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","volume":"39","author":"GT Motz","year":"2013","unstructured":"Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61\u201373.","journal-title":"Immunity"},{"key":"812_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480\u20139.","journal-title":"Nature."},{"key":"812_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014\u201322.","journal-title":"Nat Immunol"},{"key":"812_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","volume":"11","author":"LB Rivera","year":"2015","unstructured":"Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015;11:577\u201391.","journal-title":"Cell Rep"},{"key":"812_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73:539\u201349.","journal-title":"Cancer Res"},{"key":"812_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for Cancer therapy. Immunity. 2016;44:1069\u201378.","journal-title":"Immunity."},{"key":"812_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205\u201314.","journal-title":"Cell."},{"key":"812_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11:702\u201311.","journal-title":"Nat Rev Immunol"},{"key":"812_CR18","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150\u201366.","journal-title":"Blood."},{"key":"812_CR19","first-page":"129","volume":"344","author":"LE Kandalaft","year":"2011","unstructured":"Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol. 2011;344:129\u201348.","journal-title":"Curr Top Microbiol Immunol"},{"key":"812_CR20","first-page":"27","volume":"1","author":"X Zhang","year":"2018","unstructured":"Zhang X, Fan J, Ju D. Insights into CD47\/SIRP\u03b1 axis-targeting tumor immunotherapy. Antib Ther. 2018;1:27\u201332.","journal-title":"Antib Ther"},{"key":"812_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nm.3965","volume":"21","author":"RH Vonderheide","year":"2015","unstructured":"Vonderheide RH. CD47 blockade as another immune checkpoint therapy for cancer. Nat Med. 2015;21:1122\u20133.","journal-title":"Nat Med"},{"key":"812_CR22","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1158\/1078-0432.CCR-15-2503","volume":"22","author":"EC Piccione","year":"2016","unstructured":"Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, et al. SIRPalpha-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. Clin Cancer Res. 2016;22:5109\u201319.","journal-title":"Clin Cancer Res"},{"key":"812_CR23","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"812_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u201372.","journal-title":"Cancer Cell"},{"key":"812_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-16-0398","volume":"5","author":"X Zhang","year":"2017","unstructured":"Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, et al. Targeting CD47 and autophagy elicited enhanced antitumor effects in non-small cell lung Cancer. Cancer Immunol Res. 2017;5:363\u201375.","journal-title":"Cancer Immunol Res"},{"key":"812_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/carcin\/bgy041","volume":"39","author":"X Zhang","year":"2018","unstructured":"Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, et al. Disrupting CD47-SIRPalpha axis alone or combined with autophagy depletion for the therapy of glioblastoma. Carcinogenesis. 2018;39:689\u201399.","journal-title":"Carcinogenesis."},{"key":"812_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-015-1140-1","volume":"15","author":"L Liu","year":"2015","unstructured":"Liu L, Yu H, Huang X, Tan H, Li S, Luo Y, et al. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity. BMC Cancer. 2015;15:170.","journal-title":"BMC Cancer"},{"key":"812_CR28","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1007\/s00253-018-9069-3","volume":"102","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, et al. Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. Appl Microbiol Biotechnol. 2018;102:6503.","journal-title":"Appl Microbiol Biotechnol"},{"key":"812_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299\u2013309.","journal-title":"Cancer Cell"},{"key":"812_CR30","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.celrep.2016.04.015","volume":"15","author":"G Jimenez-Valerio","year":"2016","unstructured":"Jimenez-Valerio G, Martinez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suarez C, et al. Resistance to Antiangiogenic therapies by metabolic Symbiosis in renal cell carcinoma PDX models and patients. Cell Rep. 2016;15:1134\u201343.","journal-title":"Cell Rep"},{"key":"812_CR31","doi-asserted-by":"publisher","first-page":"e2720","DOI":"10.1038\/cddis.2017.137","volume":"8","author":"W Shen","year":"2017","unstructured":"Shen W, Zhang X, Fu X, Fan J, Luan J, Cao Z, et al. A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor. Cell Death Dis. 2017;8:e2720.","journal-title":"Cell Death Dis"},{"key":"812_CR32","doi-asserted-by":"publisher","first-page":"9145","DOI":"10.1007\/s00253-016-7640-3","volume":"100","author":"B Zhang","year":"2016","unstructured":"Zhang B, Fan J, Zhang X, Shen W, Cao Z, Yang P, et al. Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy. Appl Microbiol Biotechnol. 2016;100:9145\u201361.","journal-title":"Appl Microbiol Biotechnol"},{"key":"812_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccr.2005.08.002","volume":"8","author":"M Palma De","year":"2005","unstructured":"De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8:211\u201326.","journal-title":"Cancer Cell"},{"key":"812_CR34","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.celrep.2014.06.059","volume":"8","author":"N Rigamonti","year":"2014","unstructured":"Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014;8:696\u2013706.","journal-title":"Cell Rep"},{"key":"812_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nbt1323","volume":"25","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25:911\u201320.","journal-title":"Nat Biotechnol"},{"key":"812_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/CMR.0000000000000396","volume":"27","author":"C Alessi","year":"2017","unstructured":"Alessi C, Scapulatempo Neto C, Viana CR, Vazquez VL. PD-1\/PD-L1 and VEGF-A\/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival. Melanoma Res. 2017;27:565\u201372.","journal-title":"Melanoma Res"},{"key":"812_CR37","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","volume":"21","author":"MN McCracken","year":"2015","unstructured":"McCracken MN, Cha AC, Weissman IL. Molecular pathways: activating T cells after Cancer cell phagocytosis from blockade of CD47 \u201cDon\u2019t eat me\u201d signals. Clin Cancer Res. 2015;21:3597\u2013601.","journal-title":"Clin Cancer Res"},{"issue":"381","key":"812_CR38","doi-asserted-by":"publisher","first-page":"eaaf2968","DOI":"10.1126\/scitranslmed.aaf2968","volume":"9","author":"Sharareh Gholamin","year":"2017","unstructured":"Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, et al. Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.aaf2968\n\n.","journal-title":"Science Translational Medicine"},{"key":"812_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, et al. Blocking \u201cdon't eat me\u201d signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Rev. 2018;32:480\u20139.","journal-title":"Blood Rev"},{"key":"812_CR40","doi-asserted-by":"publisher","first-page":"14802","DOI":"10.1038\/ncomms14802","volume":"8","author":"PA Betancur","year":"2017","unstructured":"Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat Commun. 2017;8:14802.","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0812-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:30Z","timestamp":1601055990000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0812-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0812-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"3 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Procedures involving BALB\/c nude mice and C57BL\/6 mice (six-week old, male) were performed in accordance with the standards of Fudan University and approved by Animal Ethical Committee of School of Pharmacy Fudan University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Song Li is the employee, and Wenzhi Tian is the founder of ImmuneOnco Biopharma (Shanghai) Co., Ltd. The other authors declare no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}